The -124C>T mutation of TERT promoter indicated a favorable prognosis in OCCC: a monoinstitutional study in China

Author:

Zhou Xiaonan1,Liu Yifei1,Hu Jue1,Zhang Jing1,Ren Min1,Ji Gang1,Cai Xu1,Bi Rui1

Affiliation:

1. Fudan University Shanghai Cancer Center, Fudan University

Abstract

Abstract Purpose Ovarian clear cell carcinoma (OCCC) is the second most common type of epithelial ovarian cancer. Patients with advanced or recurrent OCCC were resistant to chemotherapy and had poor prognosis. The purpose of this study was to identify specific prognostic markers in ovarian clear cell carcinoma. Methods A cohort of 169 patients with OCCC were enrolled, and their clinicopathological features were reviewed. Mutations in the TERT promoter and PIK3CA gene were detected by Sanger sequencing in 87 and 109 cases, respectively. Immunohistochemical markers for ARID1A, HDAC6, Cyclin E1, and p53 were stained on the tissue microarrays. Kaplan-Meier curves and Cox regression analysis were used to assess the correlation between these parameters and prognosis. Results The overall survival (OS) and progression-free survival (PFS) of patients with the − 124 C > T mutation in the TERT promoter were significantly longer than those of wild-type patients. The − 124 C > T mutation was an independent factor associated with a favorable OS. Patients with the − 124 C > T mutation were more likely to have a normal preoperative serum CA125 level (P = 0.017), a higher prevalence of single nucleotide polymorphism (SNP) (P = 0.014), and a lower probability of relapse (P = 0.025) than wild-type patients. No correlation between other factors and prognosis was observed in this cohort. Conclusion Our results suggest that the − 124C > T mutation in the TERT promoter may serve as a favorable prognostic factor for overall survival in patients with OCCC.

Publisher

Research Square Platform LLC

Reference44 articles.

1. A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas;Arita H;Acta Neuropathol Commun,2016

2. NCCN Guidelines(R) Insights: Ovarian Cancer, Version 3.2022;Armstrong DK;J Natl Compr Canc Netw,2022

3. CCNE1 copy-number gain and overexpression identify ovarian clear cell carcinoma with a poor prognosis;Ayhan A;Mod Pathol,2017

4. ARID1A-mutated ovarian cancers depend on HDAC6 activity;Bitler BG;Nat Cell Biol,2017

5. Blateau P, Coyaud E, Laurent E, Beganton B, Ducros V, Chauchard G, Vendrell JA, Solassol J (2020) TERT Promoter Mutation as an Independent Prognostic Marker for Poor Prognosis MAPK Inhibitors-Treated Melanoma. Cancers (Basel) 12

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3